TBC Pfizer Australia Pty Ltd
Product name
TBC
Sponsor
Accepted date
Mar-2024
Active ingredients
marstacimab
Proposed indication
Indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in
hemophilia.
hemophilia.
Application type
A (new medicine)
Publication date
Mar-2024